Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 552,023
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Phone: 1-800-474-2737
Night_Owl_Biotech
Night_Owl_Biotech Mar. 15 at 5:21 PM
Attached is a graph that compares actual FY25 revenues & 5-year (FY26 - FY30) analyst consensus revenue estimates of $MIRM $TARS & $TVTX The raw data used to compile the graph is provided at the bottom right. Note analysts project TARS & TVTX to generate virtually identical revenues by year & cumulatively over the next 5 years as MIRM yet both trade at sharply lower market caps. Both TARS & TVTX also generated higher gross profit margins (by 7 & 13%) on FY25 revenues v MIRM. The objective of this post is to identify the disconnect in revenue multiples of TARS & TVTX. This is in no way to bash MIRM. MIRM just posted a very respectable Q425 beat. TVTX has a meaningful 4/13/26 inflection point via Filspari PDUFA for FSGS. There is evidence that suggests a 2nd PDUFA extension is possible. We're genuinely curious if there's any other data driven reason for the disconnect in multiples. This is not investment advice. There may be very good reason. $XBI $IBB
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Mar. 14 at 9:46 PM
Attached see $SNDX valuation, analyst revenue estimates & related multiples compared to $DAWN 's M&A exit valuation. If DAWN's market cap (post M&A announcement) is now 1.03X DAWN 5-year analyst consensus, would SNDX command a higher 5-year multiple than 1.03X in a hypothetical M&A exit (excluding cash/debt) because; 1. SNDX revenues generated higher gross profit margins than DAWN in FY2025 (SNDX 96% to DAWN 90%)? 2. SNDX revenues come from 2 FDA approved therapies compared to DAWN's 1 FDA approved therapy (in theory lowering risk to an acquirer)? 3. SNDX 2 products both appear to have longer patent lives (Niktimvo FY36, Revuforj 6/8/37) than DAWN's Ojemda (June 35)? We're only asking the question. This is not investment advice. $INCY $XBI $IBB
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Mar. 14 at 4:08 PM
$NBIX 10-year analyst consensus revenue estimates versus $ASND & $BBIO. Analysts forecast NBIX will generate considerably more revenues than both ASND & BBIO yet NBIX trades at meaningfully lower valuations than both. NBIX product sales generated higher gross profit margins than both in FY2025 as well The objective of this post is to identify the apparent disconnect in NBIX’s valuation using these 2 peers as comparables for valuation (sharing the math). This is in no way to put down nor bash ANSD or BBIO. Both appear great commercial-stage non-oncology focused bios. We understand there is a rumor ASND is a near-term M&A candidate. If drugs are worth some NPV and/or multiple of projected sales, and NBIX trades at meaningfully lower multiples of analyst projected sales then does that suggest NBIX’s risk v reward profile is as compelling as ASND & BBIO? We’d genuinely like to understand a data driven reason the apparent disconnect is warranted. This is not investment advice. $XBI $IBB
2 · Reply
Diefreeandsell
Diefreeandsell Mar. 13 at 7:54 PM
$IBRX $XBI $IBB $ARKK $TNA Pretty soon they'll all be Banking with the "World Bank of NK Cells". If ImmunityBio has excess capacity, they could act as a specialized CDMO for other biotechs. This would generate high-margin "service revenue" while their own drugs like ANKTIVA continue their market ramp. BTW NANT GLOBAL Blockchain coming Soon, Shiong Style!
0 · Reply
Diefreeandsell
Diefreeandsell Mar. 13 at 4:55 PM
$IBRX $XBI $IBB $QQQ $MRNA This "World Bank of NK Cells" is a huge deal. No supply shortage for global rollout and none of the analysts have any sales projections outside of USA in their Price targets. What about co acting as CDMO mrf for other BP co's usin 'GMP-IN_A_BOX' Leonardo ai mfr tech?
1 · Reply
GlassIsHalfEmpty
GlassIsHalfEmpty Mar. 13 at 3:42 PM
$IBRX $XBI $IBB $QQQ $FATE This has to be worth billions. Proprietary AI robotic driven mfr bioreactors!
2 · Reply
Diefreeandsell
Diefreeandsell Mar. 13 at 3:00 PM
$IBRX $XBI $IBB $QQQ $FATE IBRX Completes Scalable Manufacturing Pathway for M-ceNK Cell Therapy Commercial Scalability: The completion of the NK2022 and NK2023 manufacturing engineering programs established a process that generates up to 5 billion cells from a single collection, yielding 8 to 10 therapeutic doses in just 12 days. This significantly lowers the potential cost of goods (COGS) compared to traditional, less efficient cell therapy manufacturing. By validating cryopreservation from over 60 donors, the company is building a "World Bank" of ready-to-use cells. This allows for an off-the-shelf delivery model, which is essential for achieving the high-volume sales necessary to drive long-term revenue. Readiness for Automation: The methods are now established for use in AI-driven automated robotic systems (NANT Leonardo). This readiness suggests future revenue growth will be supported by a highly efficient, automated production line rather than labor-intensive manual processes.
0 · Reply
OceanThunder7
OceanThunder7 Mar. 13 at 1:56 PM
I have been saying and will say it again on $IVVD shares are tight, very tight. $IBB $XBI $BIB $QQQ
0 · Reply
thinkandpick
thinkandpick Mar. 12 at 4:17 PM
$CCLD $XBI $LABU $IBB $XLV CareCloud (CCLD) announces superb results and bright outlook for 2026! Based also on the multiples EV-to-Revenue and EV-to-adj. EBITDA, CCLD must be the most undervalued stock in the healthcare sector! https://www.globenewswire.com/news-release/2026/03/12/3254477/16541/en/CareCloud-Reports-Record-Net-Income-and-First-Full-Year-Positive-EPS-Since-IPO-Exceeds-Revenue-Guidance-and-Issues-2026-Growth-Outlook-Introduces-AI-Products.html
0 · Reply
OceanThunder7
OceanThunder7 Mar. 12 at 1:17 PM
$IVVD These are stats I look for, sub-5 #Phase3 Active Positions Holders Shares Increased Positions 75 114,960,406 Decreased Positions 27 12,588,461 Held Positions 23 123,924,350 As you can see institutions were busy in Q4! $IBB $XBI $BIB $SPY
0 · Reply
Latest News on IBB
Revenge Of The Dividend Stocks

Feb 7, 2026, 8:15 AM EST - 5 weeks ago

Revenge Of The Dividend Stocks

AAPL AMH AMT ARKK CDL CGDG CHAT


IBB: Beyond The 2025 Surge, Biotech Breakout

Jan 27, 2026, 5:10 AM EST - 6 weeks ago

IBB: Beyond The 2025 Surge, Biotech Breakout


IBB: Biotech's Hot Streak May Cool

Jan 26, 2026, 6:22 AM EST - 6 weeks ago

IBB: Biotech's Hot Streak May Cool


Funding for Risky Biotechs Is Returning

Jan 12, 2026, 12:00 PM EST - 2 months ago

Funding for Risky Biotechs Is Returning

XBI


3 Potential Mid-Cap Biotech Buyout Targets In 2026

Dec 3, 2025, 6:22 PM EST - 3 months ago

3 Potential Mid-Cap Biotech Buyout Targets In 2026

COGT TVTX XBI CYTK


'Fast Money' traders talk how to play biopharma space

Nov 11, 2025, 6:56 PM EST - 4 months ago

'Fast Money' traders talk how to play biopharma space

XLV


Trade Tracker: Jason Snipe buys the IBB

Oct 17, 2025, 1:30 PM EDT - 5 months ago

Trade Tracker: Jason Snipe buys the IBB


Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

Sep 9, 2025, 10:41 AM EDT - 6 months ago

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

XBI


Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI

Jul 6, 2025, 11:12 AM EDT - 9 months ago

Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI

XBI


Fast Money: WTI, IBB, UBER, CAT

Jun 13, 2025, 6:20 PM EDT - 9 months ago

Fast Money: WTI, IBB, UBER, CAT

UBER CAT


IBB: Now Is The Time To Be Contrarian

May 29, 2025, 10:59 AM EDT - 10 months ago

IBB: Now Is The Time To Be Contrarian


New vaccine chief rocks pharmaceutical stocks

May 7, 2025, 11:13 AM EDT - 11 months ago

New vaccine chief rocks pharmaceutical stocks

BNTX MRNA NVAX PFE GSK SRPT XBI


Sell into strength in pharma, says Mizuho's Jared Holz

Apr 11, 2025, 7:17 PM EDT - 1 year ago

Sell into strength in pharma, says Mizuho's Jared Holz

XBI


Invest In A New Biotech Bull Market With XBI And IBB

Mar 2, 2025, 8:33 AM EST - 1 year ago

Invest In A New Biotech Bull Market With XBI And IBB

XBI


iShares Biotechnology ETF: Playing Defense

Dec 10, 2024, 1:33 PM EST - 1 year ago

iShares Biotechnology ETF: Playing Defense


Final Trade: Euro, IBB, SMH, NEM

Nov 20, 2024, 6:21 PM EST - 1 year ago

Final Trade: Euro, IBB, SMH, NEM

SMH NEM


Night_Owl_Biotech
Night_Owl_Biotech Mar. 15 at 5:21 PM
Attached is a graph that compares actual FY25 revenues & 5-year (FY26 - FY30) analyst consensus revenue estimates of $MIRM $TARS & $TVTX The raw data used to compile the graph is provided at the bottom right. Note analysts project TARS & TVTX to generate virtually identical revenues by year & cumulatively over the next 5 years as MIRM yet both trade at sharply lower market caps. Both TARS & TVTX also generated higher gross profit margins (by 7 & 13%) on FY25 revenues v MIRM. The objective of this post is to identify the disconnect in revenue multiples of TARS & TVTX. This is in no way to bash MIRM. MIRM just posted a very respectable Q425 beat. TVTX has a meaningful 4/13/26 inflection point via Filspari PDUFA for FSGS. There is evidence that suggests a 2nd PDUFA extension is possible. We're genuinely curious if there's any other data driven reason for the disconnect in multiples. This is not investment advice. There may be very good reason. $XBI $IBB
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Mar. 14 at 9:46 PM
Attached see $SNDX valuation, analyst revenue estimates & related multiples compared to $DAWN 's M&A exit valuation. If DAWN's market cap (post M&A announcement) is now 1.03X DAWN 5-year analyst consensus, would SNDX command a higher 5-year multiple than 1.03X in a hypothetical M&A exit (excluding cash/debt) because; 1. SNDX revenues generated higher gross profit margins than DAWN in FY2025 (SNDX 96% to DAWN 90%)? 2. SNDX revenues come from 2 FDA approved therapies compared to DAWN's 1 FDA approved therapy (in theory lowering risk to an acquirer)? 3. SNDX 2 products both appear to have longer patent lives (Niktimvo FY36, Revuforj 6/8/37) than DAWN's Ojemda (June 35)? We're only asking the question. This is not investment advice. $INCY $XBI $IBB
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Mar. 14 at 4:08 PM
$NBIX 10-year analyst consensus revenue estimates versus $ASND & $BBIO. Analysts forecast NBIX will generate considerably more revenues than both ASND & BBIO yet NBIX trades at meaningfully lower valuations than both. NBIX product sales generated higher gross profit margins than both in FY2025 as well The objective of this post is to identify the apparent disconnect in NBIX’s valuation using these 2 peers as comparables for valuation (sharing the math). This is in no way to put down nor bash ANSD or BBIO. Both appear great commercial-stage non-oncology focused bios. We understand there is a rumor ASND is a near-term M&A candidate. If drugs are worth some NPV and/or multiple of projected sales, and NBIX trades at meaningfully lower multiples of analyst projected sales then does that suggest NBIX’s risk v reward profile is as compelling as ASND & BBIO? We’d genuinely like to understand a data driven reason the apparent disconnect is warranted. This is not investment advice. $XBI $IBB
2 · Reply
Diefreeandsell
Diefreeandsell Mar. 13 at 7:54 PM
$IBRX $XBI $IBB $ARKK $TNA Pretty soon they'll all be Banking with the "World Bank of NK Cells". If ImmunityBio has excess capacity, they could act as a specialized CDMO for other biotechs. This would generate high-margin "service revenue" while their own drugs like ANKTIVA continue their market ramp. BTW NANT GLOBAL Blockchain coming Soon, Shiong Style!
0 · Reply
Diefreeandsell
Diefreeandsell Mar. 13 at 4:55 PM
$IBRX $XBI $IBB $QQQ $MRNA This "World Bank of NK Cells" is a huge deal. No supply shortage for global rollout and none of the analysts have any sales projections outside of USA in their Price targets. What about co acting as CDMO mrf for other BP co's usin 'GMP-IN_A_BOX' Leonardo ai mfr tech?
1 · Reply
GlassIsHalfEmpty
GlassIsHalfEmpty Mar. 13 at 3:42 PM
$IBRX $XBI $IBB $QQQ $FATE This has to be worth billions. Proprietary AI robotic driven mfr bioreactors!
2 · Reply
Diefreeandsell
Diefreeandsell Mar. 13 at 3:00 PM
$IBRX $XBI $IBB $QQQ $FATE IBRX Completes Scalable Manufacturing Pathway for M-ceNK Cell Therapy Commercial Scalability: The completion of the NK2022 and NK2023 manufacturing engineering programs established a process that generates up to 5 billion cells from a single collection, yielding 8 to 10 therapeutic doses in just 12 days. This significantly lowers the potential cost of goods (COGS) compared to traditional, less efficient cell therapy manufacturing. By validating cryopreservation from over 60 donors, the company is building a "World Bank" of ready-to-use cells. This allows for an off-the-shelf delivery model, which is essential for achieving the high-volume sales necessary to drive long-term revenue. Readiness for Automation: The methods are now established for use in AI-driven automated robotic systems (NANT Leonardo). This readiness suggests future revenue growth will be supported by a highly efficient, automated production line rather than labor-intensive manual processes.
0 · Reply
OceanThunder7
OceanThunder7 Mar. 13 at 1:56 PM
I have been saying and will say it again on $IVVD shares are tight, very tight. $IBB $XBI $BIB $QQQ
0 · Reply
thinkandpick
thinkandpick Mar. 12 at 4:17 PM
$CCLD $XBI $LABU $IBB $XLV CareCloud (CCLD) announces superb results and bright outlook for 2026! Based also on the multiples EV-to-Revenue and EV-to-adj. EBITDA, CCLD must be the most undervalued stock in the healthcare sector! https://www.globenewswire.com/news-release/2026/03/12/3254477/16541/en/CareCloud-Reports-Record-Net-Income-and-First-Full-Year-Positive-EPS-Since-IPO-Exceeds-Revenue-Guidance-and-Issues-2026-Growth-Outlook-Introduces-AI-Products.html
0 · Reply
OceanThunder7
OceanThunder7 Mar. 12 at 1:17 PM
$IVVD These are stats I look for, sub-5 #Phase3 Active Positions Holders Shares Increased Positions 75 114,960,406 Decreased Positions 27 12,588,461 Held Positions 23 123,924,350 As you can see institutions were busy in Q4! $IBB $XBI $BIB $SPY
0 · Reply
OceanThunder7
OceanThunder7 Mar. 11 at 7:52 PM
$IVVD 2 Billion market cap is feasible on phase3 approval that would be roughy 7 bucks a share! A nice return $IBB $SPY $QQQ
0 · Reply
OceanThunder7
OceanThunder7 Mar. 11 at 6:03 PM
$BIB $IBB $IVVD $QQQ $XBI Let’s goooooo Bulls
0 · Reply
OceanThunder7
OceanThunder7 Mar. 11 at 3:01 PM
$IVVD Massive Buying! Just saying $QQQ $IBB $XBI $BIB
0 · Reply
OceanThunder7
OceanThunder7 Mar. 11 at 2:07 PM
$IVVD Risk vs. Reward stock sub-5, back over 1.91 and close we are headed back towards testing resistance at 2.24 on 5x potential $IBB $XBI $BIB
0 · Reply
clan
clan Mar. 11 at 2:20 AM
$MNKD Trolls r idiots. 🤑CEO, Lasagna, puts his own pocket change where his mouth is! Buys 100,000 shares on open market! For the good of all Mannkind. $SPY $MRK $IBB
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Mar. 11 at 2:14 AM
The attachment compares $SLNO 7-year analyst consensus revenue estimates to the same 7-year revenue forecasts prepared by the management/BOD of 15 comm'l-stage peers that exited via M&A. The table is sorted lowest cumulative 7-year revenue forecast to highest (with M&A exit valuations noted). Analysts forecast SLNO to generate more revenues over the next 7-years than GBT, RETA & $FOLD mgmt/BOD forecast for their products post acquisition. The 3 were acquired for enterprise values of $4.8 to $7.0B. SLNO generated 98% gross profit margins in FY25. All 3 peers forecast a lower gross profit margin on their product sales. If analysts forecast SLNO to generate more cumulative revenues over the next 7 years, does this suggest SLNO would be worth roughly the same as GBT, RETA & FOLD in a hypothetical M&A exit (assuming SLNO analyst consensus revenue estimates were credible)? This is a question for SLNO related investors. This is not investment advice. $RYTM $XBI $IBB
1 · Reply
Billianas
Billianas Mar. 10 at 8:34 PM
$IPHA this one is definitly going under 1$ and will face nasdaq compliance issues. You can buy it at discount around .50$ or less, just a matter of weeks. $XBI $IBB
0 · Reply
Floridahurricanehater
Floridahurricanehater Mar. 10 at 4:45 PM
$QQQ $SPY $DJIA $XBI $IBB. https://x.com/drpatrick/status/2030802421111459846?s=12
0 · Reply
Billianas
Billianas Mar. 10 at 1:56 PM
$NBTX overpriced, wait for 15$ level for entry. $XBI $IBB
0 · Reply
OceanThunder7
OceanThunder7 Mar. 10 at 1:36 PM
$IVVD 250k shares purchased GO TIME $IBB $SPY $XBI $BIB
0 · Reply
OceanThunder7
OceanThunder7 Mar. 10 at 1:04 PM
$IVVD The appointment of Dr. Michael Mina as Chief Medical Officer (CMO) on March 5, 2026, has been viewed as a positive strategic catalyst by the market. Analysts suggest his background in infectious disease and public communication will strengthen the company's clinical execution and market education efforts. Consensus Rating: Wall Street maintains a "Strong Buy" consensus for IVVD. Price Targets: Analysts have set an average price target of $8.75, with some reaching as high as $10.00, suggesting significant potential upside. $IBB $XBI $BIB $SPY
1 · Reply
PickAlpha
PickAlpha Mar. 10 at 11:55 AM
PickAlpha Morning Report - Company News: 2026.03.10 News Analysis - 1/5: Korro Bio prices $85M PIPE private placement of common stock and pre-funded warrants | View: Recent funding removes near-term liquidity concerns… $KRRO $XBI $IBB
0 · Reply